CHMP Backs Baricitinib, Lifmior for Plaque Psoriasis and More CHMP Backs Baricitinib, Lifmior for Plaque Psoriasis and More

The EMA ' s CHMP recommended baricitinib for rheumatoid arthritis and Lifmior for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis.International Approvals
Source: Medscape Nurses Headlines - Category: Nursing Tags: Rheumatology News Alert Source Type: news